Global R&D Pipeline
My Favorite
Hot Targets:
CD28
Back
Total number of drugs
116
Phase II and later clinical stages
4.3%
Involving companies
100
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endometrial (Rondo) | Endometrial (Rondo) | Bispecific antibody | Neoplasms Urogenital Diseases | CD28 inhibitors | Rondo Therapeutics, Inc. | Rondo Therapeutics, Inc. | Discovery | - | - | - | - | - | - | - | - | - | Endometrial (Rondo) | - | - | detail > | |
| CN118541387 | CN118541387 | Monoclonal antibody | Neoplasms Immune System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases | - | Biond Biologics Ltd. | Biond Biologics Ltd. | Discovery | - | - | - | - | - | - | - | - | - | CN118541387 | - | - | detail > | |
| WO2023076912 | WO2023076912 | CAR-T | Neoplasms | - | Gavish-Galilee Bio Applications LtdImmPACT Bio USA, Inc. | ImmPACT Bio USA, Inc.Gavish-Galilee Bio Applications Ltd | Discovery | - | - | - | - | - | - | - | - | - | WO2023076912 | - | - | detail > | |
| ODC-αCD28 | ODC-αCD28 | Cytokines | Immune System Diseases | CD28 inhibitors | Trutino Biosciences, Inc. | Trutino Biosciences, Inc. | Discovery | - | - | - | - | - | - | - | - | - | ODC-αCD28 | - | - | detail > | |
| NILK-3801 | NILK-3801 | Bispecific antibody | Neoplasms | CD28 agonists GPC3 inhibitors ADCC T lymphocytes stimulants | LamKap Bio beta AG | LamKap Bio beta AG | Discovery | - | - | - | - | - | - | - | - | - | NILK-3801 | - | - | detail > | |
| EV-201 | EV-201 | Exosomes | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | CD28 inhibitors CD80 inhibitors | eV Therapeutics, Inc. | eV Therapeutics, Inc. | Discovery | - | - | - | - | - | - | - | - | - | EV-201 | - | - | detail > | |
| CN117843809 | CN117843809 | Fusion protein | Neoplasms | - | Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd. | Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd. | Discovery | - | - | - | - | - | - | - | - | - | CN117843809 | - | - | detail > | |
| WO2024026496 | WO2024026496 | Monoclonal antibody | Neoplasms Hemic and Lymphatic Diseases Other Diseases | - | Compugen Ltd.Bristol Myers Squibb Co. | Compugen Ltd.Bristol Myers Squibb Co. | Discovery | - | - | - | - | - | - | - | - | - | WO2024026496 | - | - | detail > | |
| ARC-152 | ARC-152 | Bispecific T-cell Engager (BiTE) | Neoplasms Digestive System Disorders | CD28 inhibitors | Third Arc Bio, Inc. | Third Arc Bio, Inc. | Discovery | - | - | - | - | - | - | - | - | - | ARC-152 | - | - | detail > | |
| WO2023215498 | WO2023215498 | Nanobody | Immune System Diseases | - | ModernaTX, Inc. | ModernaTX, Inc. | Discovery | - | - | - | - | - | - | - | - | - | WO2023215498 | - | - | detail > |
Total 116 data
1
2
3
4
5
6
...
11
12
